Uterine Diseases
================

Uterine diseases include malignant diseases, such as endometrial cancer and cervical cancer, and benign diseases, which include mainly uterine myoma (*myoma uteri*, *uterus myomatosus*) and endometriosis.

Endometrial cancer
------------------

Endometrial cancer is the fourth-most-common cancer in Europe and the sixth-most-common cancer worldwide, with the majority of cases arising in post-menopausal women (Ferlay et al., [@B27]). For 2010, 303,071 new cases and 77,671 deaths were estimated (Ferlay et al., [@B27]). Most endometrial cancers are sporadic and only 10% of cases are familiar (Amant et al., [@B3]; Ryan et al., [@B69]). The sporadic cases can be divided into two subgroups: type 1, the estrogen-dependent endometrioid carcinomas (80%); and type 2, the poorly differentiated, more aggressive form, which is considered to be estrogen independent (20%; Inoue, [@B36]). Type 1 endometrial cancer is related to exposure to estrogens (of endogenous or exogenous origins) that is not opposed by progesterone or synthetic progestins. This exposure increases the mitotic activity of endometrial cells, along with the number of DNA replication errors and can lead to somatic mutations that result in a malignant phenotype (Inoue, [@B36]). Development of endometrial cancer is also associated with a number of risk factors, such as obesity, nulliparity, early age at menarche, late onset of menopause, among others (Wallace et al., [@B86]). In the last few years, it has also been suggested that inflammation contributes to the initiation and progression of endometrial cancer (Wallace et al., [@B86]). The prostaglandins (PGs) are mediators of inflammation, and they have important roles in the pathogenesis of endometrial cancer. PGE2 and PGF2α are formed locally in cancerous endometrium, where in autocrine/paracrine manners, they can stimulate cell proliferation, cell adhesion, cell migration, and angiogenesis (Sales et al., [@B72], [@B71]; Wallace et al., [@B86]).

Cervical cancer
---------------

Cervical cancer is the seventh-most-common cancer in women in Europe and the third-most-common cancer worldwide. The majority of cases are detected in developing countries, where it accounts for 13% of all female cancers (Ferlay et al., [@B27]). For 2010, 553,119 new cases, and 288,109 deaths were estimated as due to cervical cancer (Ferlay et al., [@B27]). The average age at onset is 45--55 years. The pathology of cervical cancer is related to infection with human papillomavirus (HPV) the DNA of which has been detected in 90% of cervical cancer cases (reviewed in Faridi et al., [@B26]). HPV, especially high-risk HPV16 and HPV18, are the vectors that confer susceptibility to neoplastic conversion or that directly induce malignant phenotypes in the infected epithelial cells by their oncoproteins E6 and E7, which block the normal functions of the tumor suppressor genes p53 and the retinoblastoma protein (pRb; reviewed in Faridi et al., [@B26]). Cervical cancer is also related to chronic inflammation of the cervix, due to cellular and molecular changes that can be triggered by human semen, which increase the concentration of cytokines and chemokines. Higher levels of PGE2 are considered as possible promoters of cervical carinogenesis (Herfs et al., [@B31]). Some studies have shown that risk of cervical cancer increases with use of oral contraceptives, and recently it has been reported that estrogens can promote HPV-induced carcinogenesis (Chung et al., [@B21]).

Uterine myomas
--------------

Uterine myomas are also known as leiomyomas or uterine fibroids (*myoma uteri* or *uterus myomatosus)*. These are benign tumors of the myometrium that occur in up to 70% of women of reproductive age (Maybin et al., [@B50]). As such, they are the most common tumors of women of reproductive age, although they have clinically significant symptoms in only one-third of the affected population (Miller, [@B51]). The majority of cases are thus asymptomatic; when symptomatic, these myomas can be linked to heavy menstrual bleeding, anemia, and even pregnancy complications, which can include difficulty conceiving and increased risk of miscarriage (Miller, [@B51]). Myomas appear after menarche and decline after menopause, which implicates estrogens as the primary factor that drive their growth. The pathophysiology of uterine myomas is far from clear. At the molecular level, several pathways were associated with this disease, including the retinoic-acid pathway, growth-factor signaling, and extracellular-matrix formation (Zaitseva et al., [@B94]). Recently, myomas have also been related to aberrant inflammation (Maybin et al., [@B50]).

Endometriosis
-------------

Endometriosis is a complex, estrogen-dependent disease that is defined as the presence of endometrial glands and stroma outside the uterine cavity (Giudice and Kao, [@B29]). It is diagnosed mainly in women of reproductive age, and estimates show that up to 15% of all pre-menopausal women, and 35--50% of women with infertility and pelvic pain are affected (Giudice and Kao, [@B29]). Ectopic endometrial tissue can be found in different parts of peritoneal cavity, thus forming three different entities: ovarian, peritoneal, and deep infiltrative endometriosis (Nisolle and Donnez, [@B56]). The pathogenesis of endometriosis is very complex and remains not completely understood. The most widely accepted is the theory on retrograde menstruation and disturbed immune system (Berkley et al., [@B9]). However, the pathogenesis also involves changes in apoptosis, cell adhesion, degradation of the extracellular matrix, angiogenesis, cell communication, loss of differentiation capacity (Hompes and Mijatovic, [@B34]), as well as alterations in other biological pathways (Giudice and Kao, [@B29]). Also environmental factors, increased local formation of estradiol, and diminished progesterone action affect the development of endometriosis (Giudice and Kao, [@B29]; Berkley et al., [@B9]). Enhanced inflammation has been seen in eutopic endometrium of endometriosis patients, and growth of the endometrium in ectopic sites leads to chronic pelvic inflammatory responses, as supported by the increased concentrations of PGE2 and PGF2α in the peritoneal fluid of endometriosis patients (Banu et al., [@B5]; Lousse et al., [@B46]). PGE2 regulates proliferation of endometriotic cells, immune suppression, and angiogenesis (Wu, [@B90]; Wu et al. [@B92], [@B91]), while both PGE2 and PGF2α promote transcription of angiogenic factors, such as vascular epithelial growth factor (Jabbour et al., [@B38]).

The Enzymes of the AKR1B Subfamily
==================================

There are two well-characterized human members of the aldo-keto reductase 1B (AKR1B) subfamily, AKR1B1 and AKR1B10. These AKR1B enzymes are known as aldose reductases, and they catalyze the reduction of aldehydes to alcohol (glucose to sorbitol in the polyol pathway, and retinal to retinol) and the reduction of a series of other substrates (Table [1](#T1){ref-type="table"}; Penning and Drury, [@B62]; Barski et al., [@B6]).

###### 

**Kinetic parameters of the AKR1B1 and AKR1B10 enzymes**.

  Substrate                                        AKR1B1   AKR1B10   References                        
  ------------------------------------------------ -------- --------- ------------ ----- ----- -------- --------------------------
  [d]{.smallcaps},[l]{.smallcaps}-Glyceraldehyde   65       33        507          563   29    52       Shen et al. ([@B75])
  4-Hydroxynonenal                                 716      50        70           31    119   3,839    Shen et al. ([@B75])
  GS-4-hydroxynonanal                              5        13        2,600        ND    ND    ND       Shen et al. ([@B75])
  [d]{.smallcaps},[l]{.smallcaps}-Glyceraldehyde   50       31        620          5.7   35    6,140    Ruiz et al. ([@B67])
  All-*trans*-retinal                              1.1      0.35      318          0.6   27    45,000   Ruiz et al. ([@B67])
  All-*trans*-retinol                              NA       NA        NA           0.4   4.3   12,750   Ruiz et al. ([@B67])
  9-*cis*-retinal                                  ND       ND        ND           0.7   0.9   1,300    Ruiz et al. ([@B67])
  PGH2                                             1.9      0.93      491          ND    ND    ND       Kabututu et al. ([@B39])
  PGH2                                             29       6.06      210          ND    ND    ND       Nagata et al. ([@B53])
  Farnesal                                         37       27        730          2.5   23    9,100    Endo et al. ([@B24])
  Geranylgeranial                                  ND       ND        ND           0.9   7.5   8,300    Endo et al. ([@B24])

*NA, no activity; ND, not determined*.

AKR1B1 is the most studied of the AKRs. The reduction of glucose by AKR1B1 during hyperglycemia has been linked to the development of tissue injury associated with diabetes. Therefore, a number of AKR1B1 inhibitors have been developed for the treatment of diabetic complications (reviewed by Liu et al., [@B44]; Ramana, [@B64]; Srivastava et al., [@B79]; Tammali et al., [@B82]). In addition to reduction of glucose to sorbitol in the polyol pathway, AKR1B1 catalyzes the reduction of further substrates (Table [1](#T1){ref-type="table"}), which include lipid peroxidation products, such as 4-hydroxynonenal, and their glutathione (GSH) conjugates, with a higher catalytic efficiency reported for the latter (Barski et al., [@B6]; Kabututu et al., [@B39]; Ramana, [@B64]; Table [1](#T1){ref-type="table"}). Recombinant AKR1B1 also acts as a PG synthase, as it can convert PGH2 into PGF2α with a lower *K*~M~ and a higher *V*~max~ compared to AKR1C3 (Kabututu et al., [@B39]). As confirmed by gene silencing, transient transfection studies, and the use of specific inhibitors, AKR1B1 is a functional PGF2α synthase (Bresson et al., [@B11]). Over the last few years, the involvement of AKR1B1 in inflammatory pathways has also been reported. By reducing GSH conjugated aldehydes, AKR1B1 indirectly stimulates NF-κB, which can lead to activation of the inflammatory cytokines and the inflammatory mediators, such as cycloxygenase-2 (COX-2; Barski et al., [@B6]; Ramana, [@B64]; Figure [1](#F1){ref-type="fig"}). AKR1B1 has also been implicated in the development of human cancers, such as liver, breast, ovarian, and cervical cancers (reviewed by Alexiou et al., [@B2]). It is also associated with resistance toward anticancer drugs, such as the anthracycline antibiotic danorubicin, and cisplatin (Tammali et al., [@B82]).

![**The implications of AKR1B and AKR1C enzymes in prostaglandin biosynthesis and action, and metabolism of lipid peroxidation-derived aldehydes**. AKR1B1 reduces lipid-peroxidation-derived aldehydes, such as 4-hydroxynonenal (HNE) and their GSH conjugates, such as the GSH conjugates of HNE (GS-HNE) to GS-DHN. GS-DHN activates the phospholiase C (PLC)/protein kinase C (PKC) pathway and transcription factor NF-κB, which stimulates expression of inflammatory mediators, such as cyclooxygenease-2 (COX-2) and thus leads to pathological inflammation and proliferation. AKR1C3 and AKR1B convert PGH2 to PGF2α, while AKR1C3 and also AKR1C2 convert PGD2 to 9α,11β-PGF2. These two prostaglandins activate the FP receptor, which in turn activates mitogen-activated protein kinase (MAPK) and NF-κB. Additionally, the MAPK inactivate peroxisome proliferator-activated receptor γ (PPARγ), which controls cell growth. By reducing PGD2, AKR1C3 and AKR1C2 prevent the non-enzymatic formation of pro-apoptotic 15d-PGJ2, which would activate PPARγ and inactivate NF-κB.](fphar-03-00034-g001){#F1}

AKR1B10 has 71% identical amino-acid residues to AKR1B1 and overlapping substrate specificities. With respect to retinols, AKR1B10 has a 100-fold higher catalytic efficiency toward all-*trans*-retinal, 9-*cis*-retinal, and 13-*cis*-retinal (Barski et al., [@B6]). AKR1B10 thus counteracts the formation of retinoic acid, a signaling molecule that is involved in the regulation of cell proliferation and differentiation. Similar to AKR1B1, AKR1B10 metabolizes the anticancer agents daunorubicin and idarubicin (Zhong et al., [@B96]). But in contrast to AKR1B1, which is ubiquitously expressed, AKR1B10 is expressed mainly in the small intestine and colon (Liu et al., [@B45]), and in different cancerous tissues (hepatocellular, lung, breast, colorectal, cervical, endometrial), although very weakly in normal tissues (Yoshitake et al., [@B93]). In colon carcinoma and lung carcinoma cells, AKR1B10 silencing induces apoptosis, decreases total phospholipids levels, and increases levels of reductive oxygen species and lipid peroxides (Wang et al., [@B87]). AKR1B10 also reduces isoprenyl aldehydes and is thus implicated in prenylation of small guanine nucleotide triphosphatases (GTPases) responsible for cell proliferation (Matsunaga et al., [@B48]; Novelli and D'Apice, [@B57]). This suggests that AKR1B10 represents an important cell-survival protein and also a novel drug target (Wang et al., [@B87]). The search for AKR1B10 inhibitors started recently and structurally diverse selective inhibitors of AKR1B10 have already been reported (Endo et al., [@B25]; Takemura et al., [@B81]; Soda et al., [@B78]). AKR1B10 is secreted from normal intestinal epithelium and cancer cell lines through a lysosome-mediated non-classical pathway, which suggests that it also represents a potential serum marker (Luo et al., [@B47]).

The AKR1B enzymes and the uterus
--------------------------------

The AKR1B1 protein is known to be widely expressed, and the published literature report its expression in normal endometrium and myometrium, where it is induced by IL-1β (Rossi et al., [@B66]), as well as in the cervix (Saraswat et al., [@B73]; Table [2](#T2){ref-type="table"}). As AKR1B1 has a high catalytic efficiency as a PGF2α synthase (Kabututu et al., [@B39]), it may be responsible for increased production of PGF2α in the secretory as well as the menstrual phases of the menstrual cycle, when the highest concentrations of PGF2α have been detected. Concurrently increased synthesis of PGF2α and PGE2 in endometrium has important implications in menstruation. PGF2α acts as a vasoconstrictor and induces myometrial contractions, while PGE2 acts as a vasodilator, which leads to increased edema (reviewed in Maybin et al., [@B50]). A significantly decreased ratio of PGF2α/PGE2 was observed in women with heavy menstrual bleeding, which might be related to decreased expression/activity of AKR1B1 or increased expression/activity of PGE2 synthase in this condition (reviewed in Maybin et al., [@B50]). PGF2α has been implicated in the development of primary dysmenorrhea, which again implies a role for AKR1B1 here (reviewed in Maybin et al., [@B50]). In contrast to AKR1B1, the expression of the *AKR1B10* gene in the endometrium, myometrium, and cervix of normal human uterus has not been reported.

###### 

**Expression of *AKR1B1* and *AKR1B10* in human uterus**.

  Isoform       Level         Tissue                                                                                                                                                                                 References
  ------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- -----------------------
                              **Endometrium**                                                                                                                                                                        
                              **Epithelial cells**                                                                                                                                     **Stromal cells**             
  **AKR1B1**    **mRNA**      Expression related to PGF2α production.                                                                                                                  Chapdelaine et al. ([@B19])   
                                                                                                                                                                                       Induced by IL-1β.             Rossi et al. ([@B66])
                              Expressed throughout the menstrual cycle without significant variations.                                                                                 Bresson et al. ([@B11])       
                              Higher expression in the menstrual phase and middle/late secretory phase.                                                                                Catalano et al. ([@B18])      
                **Protein**   Immunohistochemical staining of luminal and glandular cells, higher expression in early proliferative and mid-late secretory phase of menstrual cycle.   Bresson et al. ([@B11])       
  **AKR1B10**                 Not evaluated.                                                                                                                                                                         
                              **Myometrium**                                                                                                                                                                         
  **AKR1B1**    **mRNA**      Low expression, no significant difference between pregnant and non-pregnant women.                                                                       Phillips et al. ([@B63])      
                              In cultured cells induced by IL-1β and TNFα.                                                                                                             Phillips et al. ([@B63])      
  **AKR1B10**                 Not evaluated.                                                                                                                                                                         
                              **Cervix**                                                                                                                                                                             
  **AKR1B1**    **Protein**   Detected by immunoblotting and immunohistochemistry.                                                                                                     Saraswat et al. ([@B73])      
  **AKR1B10**                 Not evaluated.                                                                                                                                                                         

The AKR1B enzymes in endometrial and cervical cancers
-----------------------------------------------------

There have been no reports of the expression of *AKR1B1* in endometrial cancer, but AKR1B1 has been detected in squamous cervical cancer and adenocarcinoma of the cervix (Saraswat et al., [@B73]; Table [3](#T3){ref-type="table"}). Increased AKR1B1 levels and increased activity detected in cervical cancer (Saraswat et al., [@B73]) may be related to its implication in inflammation, including its promotion of PGF2α synthesis. It may also be associated with resistance to chemotherapeutics, which is a major problem in treatment of this disease. AKR1B10 has been revealed in cancerous endometrium and cervical cancer (Yoshitake et al., [@B93]; Table [3](#T3){ref-type="table"}). In the later the expression correlated with tumor recurrence after surgery and the authors suggested that AKR1B10 represents a promising marker (Yoshitake et al., [@B93]). Similarly, as reported in lung cancer (Fukumoto et al., [@B28]), higher percentages of AKR1B10-positive cells were seen in squamous cell carcinoma (cervical cancer patients), as compared to adenocarcinoma (endometrial cancer patients; Yoshitake et al., [@B93]). AKR1B10 appears to be specific for this distinct morphology, where it might be associated with reduction of retinal to retinol, and thus with decreased levels of retinoic acid. This will remove the ligands for the retinoic acid receptors (RARs) and retinoid X receptors (RXRs), and thus prevent cell differentiation. At present, there appear to be no reports on the expression of AKR1B1 and AKR1B10 in uterine myomas or endometriosis.

###### 

**Expression of *AKR1B1* and *AKR1B10* in uterine diseases**.

  Isoform       Level         Tissue                                                                                                                            References
  ------------- ------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------
                              **Endometrial cancer**                                                                                                            
  **AKR1B1**                  Not evaluated.                                                                                                                    
  **AKR1B10**   **Protein**   Staining in 16% cases, 10% to 20% of cells in AKR1B10-positive cases.                                                             Yoshitake et al. ([@B93])
                              No correlation with age, clinical stage, pathological features, histological grade, metastasis, and recurrence after surgery.     
                              **Cervical cancer**                                                                                                               
  **AKR1B1**    **Protein**   Detected in squamous cervical cancer and adenocarcinoma of the cervix, higher protein levels, and enzymatic activity in cancer.   Saraswat et al. ([@B73])
  **AKR1B10**                 Staining in 20% cases, 90% of cells in AKR1B10-positive cases; correlates with tumor recurrence after surgery.                    Yoshitake et al. ([@B93])
                              **Endometriosis**                                                                                                                 
  **AKR1B1**                  Not evaluated.                                                                                                                    
  **AKR1B10**                 Not evaluated.                                                                                                                    
                              **Uterine myomas**                                                                                                                
  **AKR1B1**                  Not evaluated.                                                                                                                    
  **AKR1B10**                 Not evaluated.                                                                                                                    

A potential role for the AKR1B enzymes in uterine diseases
----------------------------------------------------------

AKR1B1 has a relatively high catalytic efficiency as a PGF2α synthase (Kabututu et al., [@B39]). PGF2α acts through FP receptor and mitogen-activated protein kinase (MAPK) signaling, which activates NF-κB and thus induces COX-2. Higher levels of COX-2 then lead to a further production of the PGs, and thus enhanced cell proliferation, cell adhesion, angiogenesis, and cytoskeleton remodeling of the endometrium (Figure [1](#F1){ref-type="fig"}; Sales et al., [@B70], [@B71]). Additionally, AKR1B1 via reduction of the GSH conjugates of lipid-aldehydes stimulates transcription of various inflammatory cytokines, chemokines, and inflammatory mediators. Lipid-peroxidation-derived aldehydes, such as 4-hydroxynonenal, are conjugated with GSH by GSH-S-transferase and reduced by AKR1B1 to the 1,4-dihydroxy-2-nonene GSH conjugate, which activates PLC, and also NF-κB and AP1 via protein kinase C (PKC; Figure [1](#F1){ref-type="fig"}; Ramana, [@B64]). Furthermore, the cytokine IL-1β stimulates *AKR1B1* expression (Rossi et al., [@B66]), which may potentiate the activation of NF-κB and may lead to a vicious inflammatory cycle. The uncontrolled inflammation is related to the development of uterine diseases, including endometrial cancer, uterine myoma, and endometriosis (Wallace et al., [@B86]; Maybin et al., [@B50]). As it is involved in inflammation via at least two possible mechanisms, AKR1B1 might also be involved in the pathogenesis of these diseases. To date, higher AKR1B1 expression has been reported only in cervical cancer (Saraswat et al., [@B73]) and there have been no reports of AKR1B1 expression in endometrial cancer, uterine myoma, and endometriosis. Endometriosis and endometrial cancer are associated with higher PGF2α concentrations in peritoneal fluid and endometriosis tissue, and increased local formation of PGF2α in cancer endometrium, respectively (Sales et al., [@B71]; Banu et al., [@B5]), thus AKR1B1 might be implicated in the pathogenesis of these diseases as well. In endometrial cancer cells, PGF2α stimulates cell proliferation, cell adhesion, migration, and angiogenesis (Sales et al., [@B71]). Also, uterine myoma is related to aberrant inflammation, and thus AKR1B1 might also have a role in this disease.

Due to the high catalytic efficiency of AKR1B10 for the reduction of all-*trans*, 9-*cis*, and 13-*cis* retinaldehydes to retinols (Kabututu et al., [@B39]), the increased levels of AKR1B10 in endometrial and cervical cancer (Yoshitake et al., [@B93]) might be linked to depletion of retinoic acid. Decreased availability of the ligand for the RARs and RXRs, will lead to a loss of cell differentiation (Figure [2](#F2){ref-type="fig"}). The oxidation of retinal to retinoic acid by retinaldehyde dehydrogenase is irreversible in a cellular context, and reduction of retinals to retinols by AKR1B10 thus counteracts the synthesis of retinoic acid (Penning, [@B60]). Indeed retinoic acid and RAR agonists inhibit the growth of the Ishikawa endometrial cancer cell line (Tanabe et al., [@B83]; Cheng et al., [@B20]) and retinoic acid stimulates differentiation of the poorly differentiated CAC-1 endometrial adenocarcinoma cell line (Carter, [@B17]). Also, a very recent report on antitumor effects of inhibitors of the retinoic-acid-metabolizing CYP26A (Goss et al., [@B30]) confirmed the protective effects of retinoic acid and suggested that AKR1B10 inhibitors might have a similar role. Interestingly, topical retinoic acid has shown activity in cervical intraepithelial neoplasia (a potentially premalignant transformation of cervical cells; Abu et al., [@B1]), which implies a decreased protective effect of retinoic acid in precancerous tissue. However, in cervical cancer cell lines, no effects (in CaSki cells) and even stimulatory effect (in HeLa cells) of all-*trans* retinoic acid have been observed. As retinoic acid does not repress the expression of the viral oncoproteins E6 and E7 of HPV types 16 and 18, which have a major role in carcinogenesis of the cervix (Myga-Nowak et al., [@B52]), this shows that retinoids might have a role only in precancerous tissue.

![**The implications of AKR1B and AKR1C enzymes in retinoid signaling**. AKR1B10, AKR1C3, and AKR1C1 catalyze the reduction of all-*trans*-retinal and 9-*cis*-retinal to their corresponding retinols, respectively. The reverse reaction is catalyzed by alcohol dehydrogenases (ADHs). Retinal is further oxidized by aldehyde dehydrogenases (ALDHs) to form retinoic acid, which by binding to the retinoic acid receptor (RAR) and the retinoid X receptor (RXR) stimulates cell differentiation. Retinoic acid is further metabolized by CYP26A to form 4-hydroxy-retinoic acid. Increased levels of AKR1B10 and AKR1C3 might be linked to depletion of retinoic acid, which deprives RAR and RXR of their ligands, and thus blocks cell differentiation.](fphar-03-00034-g002){#F2}

Suppressed action of retinoic acid might also be related to the benign proliferative diseases, such as uterine myoma and endometriosis. Indeed, decreased expression of alcohol dehydrogenase 1 (ADH1) and aldehyde dehydrogenase 1 (ALDH1), which are responsible for the conversion of retinol to retinal and of retinal to retinoic acid, respectively, has been reported in uterine fibroids (Zaitseva et al., [@B94]). While decreased retinoid uptake, formation and action, and increased retinoic-acid metabolism have been shown in endometriosis (Pavone et al., [@B58]). It has also been suggested that deficient retinoic-acid action in endometriosis leads to decreased levels of 17β-hydroxysteroid dehydrogenase type 2, which converts the potent estradiol to the less active estrone. This leads to increased levels of the potent mitogen estradiol and thus increased cell proliferation (reviewed in Bulun, [@B13]). However, evaluation of the expression and role of *AKRB10* in these diseases awaits further studies.

AKR1B10 has a high catalytic efficiency for reduction of isoprenyl aldehydes, farnesal (FAL), and geranylgeranial (GGAL; Endo et al., [@B24]) and is thus also involved in prenylation of cellular proteins (Figure [3](#F3){ref-type="fig"}). Proteins that undergo prenylation include small GTPases: RAS and RHO proteins (Novelli and D'Apice, [@B57]). These prenylated proteins are integral components of signaling networks that regulate cell proliferation, differentiation, migration, and apoptosis (Berndt et al., [@B10]; Novelli and D'Apice, [@B57]). Prenylation involves transfer of farnesyl pyrophosphate (15-carbon chain) or geranylgeranyl pyrophospate (20-carbon chain), which both originate from the mevalonate pathway, to cysteine residue of these proteins and is catalyzed by farnesyltranserase (FT) and geranylgeranyltransferase 1 (GGT1) and GGT2, respectively. Prenylcystein lyase (PCLY) catalyzes the reverse reaction that releases FAL and GGAL from prenylated proteins (Digits et al., [@B22]). Farnesyl pyrophosphate and geranylgeranyl pyrophosphate thus serve as substrates for FT and GGT1/GGT2 but can as well be dephosphorylated to form farnesol (FOH) and geranylgeranyol (GGOH; reviewed by Matsunaga et al., [@B48]). FOH and GGOH are oxidized to FAL and GGAL by ADHs and further to farnesoic acid (FA), geranylgeranoic acid (GGA), and other metabolites. The reduction of FAL and GGAL to FOH and GGOH, catalyzed by AKR1B enzymes, thus recovers substrates for further phosphorylation to corresponding pyrophosphates. Additionally, AKR1B10 with the highest catalytic efficiency for reduction of GGAL prevents formation of GGA and other metabolites with diverse biological effect, including induction of apoptosis (reviewed in Matsunaga et al., [@B48]). In this manner AKR1B10 prevents formation of pro-apoptotic metabolites and promotes prenylation and activation of small GTPases and further intracellular signaling (reviewed in Matsunaga et al., [@B48]). Inhibitors of FT (FTI) and GGT1 (GT1I) have already been developed as potential anticancer agents and several clinical trials have been reported for FTI, while the first GGT1I recently entered the clinic (Berndt et al., [@B10]). FTIs have shown a very limited application in cancer patients, therefore there is a need for novel drug targets within the prenylation pathway, with a potential for AKR1B10. As a secretory protein (Luo et al., [@B47]), AKR1B10 also represents a potential novel biomarker not only of liver and lung cancer, but also of uterine cancers, and especially of cervical cancer.

![**The implications of AKR1B and AKR1C enzymes in protein prenylation**. Prenylation involves transfer of farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) by farnesyltranserase (FT) and geranylgeranyltransferase 1 and 2 (GGT1 and GGT2), respectively, to various proteins including small GTPases (RAS and RHO). The reverse reaction that releases farnesal (FAL) and geranylgeranial (GGAL) is catalyzed by prenylcystein lyase (PCLY). Farnesyl pyrophosphate and geranylgeranyl pyrophosphate thus serve as substrates of FT and GGT1/GGT2 but can also be dephosphorylated to form farnesol (FOH) and geranylgeranyol (GGOH). FOH and GGOH are oxidized to FAL and GGAL by alcohol dehydrogenases (ADHs) and by yet unidentified enzymes to farnesoic acid (FA), geranylgeranoic acid (GGA) and other metabolites. The reduction of FAL and GGAL to FOH and GGOH is catalyzed by AKR1B and AKR1C enzymes. This reaction indirectly recovers substrates for further formation of active prenyl-pyrophosphates. Additionally, reduction of GGAL to GGOH prevents formation of GGA and the metabolites with potential apoptotic effects. (Adopted from Endo et al., [@B24].)](fphar-03-00034-g003){#F3}

The Enzymes of the AKR1C Subfamily
==================================

The AKR1C subfamily includes four human enzymes AKR1C1, AKR1C2, AKR1C3, and AKR1C4, which share high percentages of amino-acid identities (84--98%). AKR1C1 and AKR1C2, for instance, differ in only seven amino-acid residues. These enzymes function *in vivo* as 3-keto-, 17-keto-, and 20-ketosteroid reductases to varying extents (Table [4](#T4){ref-type="table"}), and they thus regulate the activity of androgens, estrogens, and progesterone, and the occupancy and transactivation of the corresponding receptors (Penning et al., [@B61]; Steckelbroeck et al., [@B80]). The AKR1C isozymes are also involved in PG metabolism (Table [4](#T4){ref-type="table"}). AKR1C3 catalyzes the formation of PGF2α from PGH2, and 9α,11β-PGF2 from PGD2, and in this manner prevents the formation of the pro-apoptotic 15-deoxy-PGJ2 (Byrns et al., [@B14]). AKR1C1 and AKR1C2, on the other hand, convert PGE2 to PGF2α and also have lower 11-ketoreductase activities to reduce PGD2 to 9α,11β-PHF2α (Nishizawa et al., [@B55]; Dozier et al., [@B23]). The AKR1C enzymes reduce isoprenyl aldehydes and may be implicated in prenylation of cellular proteins (Table [4](#T4){ref-type="table"}; Matsunaga et al., [@B48]). Recently it has been reported that AKR1C3 also catalyzes reduction of retinaldehydes, especially 9-*cis*-retinaldehyde with surprisingly higher catalytic efficiency as compared to other substrates (Ruiz et al., [@B68]). The AKR1C enzymes act as phase I metabolism enzymes, and they are responsible for metabolism and clearance of different xenobiotics, and are thus implicated in resistance to treatments with different drugs (Huang et al., [@B35]; Le Calve et al., [@B41]). The AKR1C enzymes also convert 5α-dihydroprogesterone (5α-DHP; Table [4](#T4){ref-type="table"}) to the 3α-hydroxy-metabolite, the most potent positive allosteric modulator of the γ-aminobutyric acid type A (GABA~A~) receptor, as well as to the less potent 20α-hydroxy-metabolite. In this manner AKR1C enzymes are implicated in the production of active neurosteroids. As 5α-pregnanes stimulate proliferation of breast cancer cells, the AKR1C enzymes are also involved in the production of pro-proliferative metabolites (Wiebe, [@B89]). AKR1C2 preferentially catalyzes the formation of 3α-hydroxy-5α-pregnane-20-one, while AKR1C1 and AKR1C3 mainly form 20α-hydroxy-metabolites (Usami et al., [@B85]). The AKR1C enzymes, except AKR1C4 which is liver specific, are expressed in different normal and diseased tissues and have thus been related to several diseases, such as lung, breast, prostate, endometrial cancer, myeloid leukemia, and others. Structurally diverse inhibitors have been reported and in spite the high amino-acid identity also selective inhibitors of individual isoforms have been reported (reviewed in Brožic et al., [@B12]; Byrns et al., [@B15]).

###### 

**Kinetic parameters of the AKR1C1, AKR1C2, and AKR1C3 enzymes**.

  Substrate             AKR1C1   AKR1C2   AKR1C3   References                                          
  --------------------- -------- -------- -------- ------------ ------- ------- ----- ------- -------- -------------------------------
  Progesterone          5.7      0.93     210      ND           ND      ND      2.8   1.04    370      Sharma et al. ([@B74])
  Progesterone          1.9      0.57     300      7.7          0.21    30      5.6   0.168   30       Beranič et al. ([@B8], [@B7])
  Estrone               ND       ND       ND       ND           ND      ND      9     0.068   7.6      Byrns et al. ([@B14])
  5α-DHP                1.1      2.6      2,400    0.6          0.48    800     ND    0.06    ND       Higaki et al. ([@B33])
  3α,5α-THP             2.0      4.4      2,200    3.1          0.26    80      ND    ND      ND       Higaki et al. ([@B33])
  20α,5α-THP            0.7      0.6      860      0.5          0.48    960     2.1   0.52    250      Higaki et al. ([@B33])
  PGD2                  ND       ND       ND       ND           ND      ND      1.1   1.4     1,270    Matsuura et al. ([@B49])
  PGD2                  140      0.015    0.11     120          ND      ND      3     3.7     1,200    Nishizawa et al. ([@B55])
  PGE2                  1,400    0.48     0.34     98           0.082   0.83    LA    LA      LA       Nishizawa et al. ([@B55])
  All-*trans*-retinal   LA       LA       LA       NA           NA      NA      1.4   0.60    430      Ruiz et al. ([@B68])
  9-*cis*-retinal       0.48     0.18     370      NA           NA      NA      0.4   13      32 500   Ruiz et al. ([@B68])
  Farnesal              3.1      1.7      550      1.1          1.8     1,600   2.6   2.7     1,100    Endo et al. ([@B24])
  Geranylgeranial       ND       ND       ND       ND           ND      ND      0.3   3.6     12,000   Endo et al. ([@B24])

*LA, low activity; NA, no activity; ND, not determined, 3α,5α-THP, 3α-hydroxy-5α-pregnane-20-one; 20α,5α-THP, 20α-hydroxy-5α-pregnane-3-one*.

The AKR1C enzymes and the uterus
--------------------------------

Expression of the *AKR1C* genes has been reported in human uterus (Nishizawa et al., [@B55]; Penning et al., [@B61]; Table [5](#T5){ref-type="table"}). In endometrium, semiquantitative RT-PCR analysis revealed significantly higher mRNA levels of *AKR1C1* in the secretory phase (Nakajima et al., [@B54]). As the concentrations of PGF2α increase during the secretory phase and PGF2α can activate the *AKR1C1* promoter (Nishizawa et al., [@B55]), this leads to increased expression of *AKR1C1*. Also mRNA levels of *AKR1C3* are the highest in the early secretory phase (Catalano et al., [@B18]), while expression of *AKR1C2* throughout the menstrual phases has not yet been examined. To date, expression at the protein/cellular levels has been studied only for AKR1C3 (Pelletier et al., [@B59]). In paraffin sections of normal endometrium no significant differences in the presence of AKR1C3 were reported during the menstrual phases (Ito et al., [@B37]). However, these authors provided no information on the specificities of their antibodies. As AKR1C1, AKR1C2, and AKR1C3 have more than 87% identical amino acids, the antibodies might well have detected all of the three isoforms; thus these data should be considered with caution.

###### 

**Expression of *AKR1C1*, *AKR1C2*, and *AKR1C3* in human uterus**.

  Isoform                      Level         Tissue                                                                                                                                                                         References
  ---------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------
                                             **Uterus**                                                                                                                                                                     
  **AKR1C1, AKR1C2,**          **mRNA**      *AKR1C2* \> *AKR1C3* \>\> *AKR1C1*                                                                                                                                             Penning et al. ([@B61])
  **AKR1C3**                                 *AKR1C3* \> *AKR1C1* \>\> *AKR1C2*                                                                                                                                             Nishizawa et al. ([@B55])
                                             **Endometrium**                                                                                                                                                                
  **AKR1C1**                   **mRNA**      Higher levels in secretory phase.                                                                                                                                              Nakajima et al. ([@B54])
                                             Induced by PGF2α.                                                                                                                                                              Nishizawa et al. ([@B55])
  **AKR1C3**                                 Higher levels in early secretory phase.                                                                                                                                        Catalano et al. ([@B18])
  **AKR1C2**                                 Not evaluated.                                                                                                                                                                 
  **AKR1C3**                   **Protein**   Epithelial cells of endometrial glands.                                                                                                                                        Pelletier et al. ([@B59])
                                             No significant difference between menstrual phases.                                                                                                                            Ito et al. ([@B37])
  **AKR1C1, AKR1C**                          Not evaluated.                                                                                                                                                                 
                                             **Myometrium**                                                                                                                                                                 
  **AKR1C1**                   **mRNA**      Significantly increased in women in spontaneous labor versus women not in labor, no difference in women with induced labor.                                                    Lee et al. ([@B42])
  **AKR1C3**                                 No difference between pregnant/non-pregnant women, no effects of cytokines.                                                                                                    Phillips et al. ([@B63])
  **AKR1C2**                                 Not evaluated.                                                                                                                                                                 
                                             **Cervix**                                                                                                                                                                     
  **AKR1C1, AKR1C2, AKR1C3**   **mRNA**      AKR1C1 \>  AKR1C2 (7-fold) AKR1C1 \>  AKR1C3 (3-fold) No difference in *AKR1C1* expression in women before/after labor; decreased *AKR1C2* and *AKR1C3* levels during labor.   Andersson et al. ([@B4])
                                             Cervical fibroblasts: *AKR1C1* and *AKR1C3* induced by IL-1β.                                                                                                                  Roberson et al. ([@B65])

The *AKR1C* genes are not expressed only in the endometrium. Expression of *AKR1C1* and *AKR1C3* has been detected also in myometrium (Lee et al., [@B42]; Phillips et al., [@B63]; Table [5](#T5){ref-type="table"}). The authors concluded that the increased *AKR1C1* expression may be responsible for the increased 20α-OHP concentrations that are associated with spontaneous labor, and they suggested that induced labor is not dependent on AKR1C1 (Lee et al., [@B42]). Expression of the *AKR1C* genes have been detected also in the human cervix (Andersson et al., [@B4]; Table [5](#T5){ref-type="table"}). In human cervical fibroblasts IL-1β significantly induced *AKR1C1* and *AKR1C3*, therefore the authors hypothesized that lower uterine infections during pregnancy, with the concomitant production of cytokines, might increase the expression of *AKR1C1* and *AKR1C3* and thus accelerate progesterone metabolism to 20α-OHP in cervical fibroblasts. This would potentially have a major impact on cervical structure, with an increase in the likelihood of a preterm birth (Roberson et al., [@B65]).

Studies have thus shown that the *AKR1C* genes *AKR1C1* and *AKR1C3* are expressed in the normal uterus within the endometrium, myometrium, and cervical canal (Table [5](#T5){ref-type="table"}). AKR1C1 is the major human 20-ketosteroid reductase, and it converts progesterone to 20α-OHP (Nishizawa et al., [@B55]; Lanišnik Rižner et al., [@B40]). AKR1C3 acts as a 17-ketosteroid reductase, and activates estrone to estradiol, while it also acts as a 20-ketosteroid reductase, albeit with 10-fold lower catalytic efficiency than that seen for AKR1C1 (Penning et al., [@B61]; Beranič et al., [@B8]). Additionally, AKR1C3 can act as PGF2α synthase (Dozier et al., [@B23]). AKR1C3 detected in endometrial glands of normal endometrium (Pelletier et al., [@B59]; Ito et al., [@B37]) may thus be related to PGF2α formation and progesterone metabolism. The higher levels of *AKR1C1* mRNA in the secretory endometrium are probably associated with increased PGF2α concentrations, and the higher levels of *AKR1C1* mRNA in myometrium, with spontaneous labor (Nakajima et al., [@B54]; Lee et al., [@B42]). In late secretory phase endometrium and in myometrium, AKR1C1 thus contributes to decreased local concentrations of progesterone. Induction of *AKR1C1* and *AKR1C3* by IL-1β might be related to preterm labor caused by uterine infection (Roberson et al., [@B65]). Finally, although AKR1C2 was reported to be the predominate AKR1C isoform of the whole uterus (Penning et al., [@B61]), its expression and its role in endometrium and myometium have not yet been studied.

The AKR1C enzymes in endometrial and cervical cancer
----------------------------------------------------

The expression of the *AKR1C* genes in endometrial cancer has been studied mainly by three groups (Table [6](#T6){ref-type="table"}). We detected *AKR1C1, AKR1C2*, and *AKR1C3* mRNA levels in paired samples of cancerous endometrium and adjacent control endometrium (Lanišnik Rižner et al., [@B40]; Šmuc and Lanišnik Rižner, [@B77]). The differences in expression were not statistically significant, but our pair-wise comparison suggested that in some patients, increased levels of AKR1C1 and/or AKR1C3 might be associated with pathophysiology of endometrial cancer. At the cellular level, Ito et al. ([@B37]) reported increased AKR1C3 immunoreactivity in endometrial hyperplasia and endometrial carcinoma. Although this was without showing any experimental data for the sections or clinical data of the patients, and without sufficient information on the antibodies, the authors suggested that AKR1C3 is one of the key enzymes in the local regulation of estrogen concentrations in endometrial malignancies (Ito et al., [@B37]). Our group used a well-characterized and specific monoclonal antibody against AKR1C3 (Lin et al., [@B43]), which stained all 10 paraffin sections of cancerous endometrium (Šmuc and Lanišnik Rižner, [@B77]). Using the same antibody, Zakhaorov et al. ([@B95]) showed weaker AKR1C3 staining in hyperplastic endometrium and cancerous endometrium, versus the normal proliferative endometrium. However, such comparisons should also be interpreted with caution, due to differences between the groups according to menopausal status, and due to the small number of patients. In contrast to women with normal endometrium (pre-menopausal; mean age, 31.5 years) and patients with endometrial hyperplasia (2 out of 8 post-menopausal; mean age, 47.8), the majority of endometrial cancer patients were post-menopausal (8 out of 12, mean age 58.4), as expected, and there was a significant age difference between the control and the endometrial cancer groups.

###### 

**Expression of *AKR1C1*, *AKR1C2*, and *AKR1C3* in uterine diseases**.

  Isoform                      Level         Tissue                                                                                                                     References
  ---------------------------- ------------- -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
                                             **Endometrial cancer**                                                                                                     
  **AKR1C1, AKR1C2, AKR1C3**   **mRNA**      No statistically significant difference (25 paired samples).                                                               Lanišnik Rižner et al. ([@B40]); Šmuc and Lanišnik Rižner ([@B77])
  **AK1C3**                    **Protein**   No statistically significant difference (16 paired samples).                                                               Šmuc and Lanišnik Rižner ([@B77])
                                             Increased expression: 50% endometrial hyperplasia, 69% endometrial carcinoma, 19% to 25% normal endometrium samples.       Ito et al. ([@B37])
                                             Glandular and luminal epithelial cells, 10/10 paraffin sections of endometrial cancer.                                     Šmuc and Lanišnik Rižner ([@B77])
                                             Weaker staining in endometrial hyperplasia (8) and endometrial cancer (12) versus normal proliferative endometrium (13).   Zakhaorov et al. ([@B95])
  **AKR1C1, AKR1C2**                         Not evaluated.                                                                                                             
                                             **Cervical cancer**                                                                                                        
  **AKR1C1, AKR1C2, AKR1C3**   **mRNA**      Increased *AKR1C1* and *AKR1C3* expression in C33A cell line transfected with truncated HPV16E6.                           Wanichwatanadecha et al. ([@B88])
  **AKR1C1, AKR1C2**           **protein**   Detected in 75% HPV positive and 43.2% HPV negative cervical cancer cases, expression correlates with HPV status.          Ueda et al. ([@B84])
                                             **Endometriosis**                                                                                                          
  **AKR1C1, AKR1C3**           **mRNA**      Significantly higher expression in ovarian endometriosis (24) versus control endometrium (10).                             Šmuc et al. ([@B76])
  **AKR1C1, AKR1C2**                         Significantly higher expression in ovarian endometriosis (24) versus normal endometrium (10).                              Hevir et al. ([@B32])
  **AKR1C3**                   **protein**   In 13/15 samples of ectopic endometrium.                                                                                   Šmuc et al. ([@B76])
                                             No significant difference between ovarian endometriosis (18) and control endometrium (9).                                  Hevir et al. ([@B32])
  **AKR1C1, AKR1C2**                         Significantly higher levels in ovarian endometriosis.                                                                      Hevir et al. ([@B32])
                                             **Uterine myomas**                                                                                                         
  **AKR1C1, AKR1C2, AKR1C3**                 Not evaluated.                                                                                                             

Among the *AKR1C* genes, expression of *AKR1C1*, *AKR1C2*, and *AKR1C3* was detected in endometrial cancer and adjacent control endometrium, and increased mRNA levels of *AKR1C1* and *AKR1C3* were seen in some patients (Lanišnik Rižner et al., [@B40]; Šmuc and Lanišnik Rižner, [@B77]). However, on average, no significant differences were observed at the mRNA level, and immunohistochemical analysis revealed lower AKR1C3 levels in the hyperplastic and cancer endometrium (Zakhaorov et al., [@B95]). It is clear here that AKR1C3 expression in endometrial cancer needs to be further studied at the protein level on a larger number of endometrial cancer samples with the specific antibodies that are available. The menopausal status of the patients should also be taken into consideration, and therefore comparisons between post-menopausal cancer endometrium and control endometrium of the same patient should be used. Additionally, the expression of AKR1C1 and AKR1C2 remain to be studied further.

The AKR1C1 and AKR1C2 enzymes have also been detected in cervical cancer patients with significant correlation to HPV infection and poorer survival rate (Ueda et al., [@B84]). Interestingly, the up-regulation of *AKR1C1* and *AKR1C3* genes have been reported in cervical cancer C33A cell line stably transfected with truncated HPV16 oncoprotein E6 (Wanichwatanadecha et al., [@B88]). The authors suggested that the increased levels of AKR1C1 and AKR1C3 may be involved in drug resistance, a major problem in treatment of cervical cancer.

The AKR1C enzymes in endometriosis
----------------------------------

Our group was the first to show expression of the *AKR1C* genes in endometriosis (Table [6](#T6){ref-type="table"}). Significantly higher mRNA levels of *AKR1C1*, *AKR1C2*, and *AKR1C3* were seen in ovarian endometriosis versus control endometrium of myoma patients and versus normal endometrium of healthy women (Šmuc et al., [@B76]; Hevir et al., [@B32]). At the protein level, AKR1C3 was detected in ectopic endometrium (Šmuc et al., [@B76]) and immunohistochemical staining showed no significant differences in AKR1C3 scores, but a significant increase in AKR1C2 total scores (Hevir et al., [@B32]). Although the comparisons to normal endometrium still need to be done, our data suggest that the AKR1C enzymes, and especially AKR1C1 and AKR1C2, may be associated with the development of ovarian endometriosis. Increased levels of AKR1C1 and AKR1C2 in endometriotic tissue might also contribute to enhanced metabolism of the protective progesterone, and to the formation of the pro-proliferative 5α-pregnanes (Wiebe, [@B89]; Beranič and Lanišnik Rižner, unpublished data). To the best of our knowledge, there have been no reports on the expression of the AKR1C enzymes in uterine myomas.

The potential role of the AKR1C enzymes in uterine diseases
-----------------------------------------------------------

AKR1C3 and AKR1C1 are involved in estradiol formation and progesterone inactivation, respectively (Penning et al., [@B61]); therefore, their increased levels in diseased endometrium might lead to enhanced proliferation stimulated by estrogens. It has long been known that estrogen actions that remain unopposed by the protective actions of progesterone are related to the development of uterine diseases, endometrial hyperplasia, endometrial cancer, and endometriosis (Inoue, [@B36]). The increased levels of AKR1C3 that have been seen in some endometrial cancer patients (Lanišnik Rižner et al., [@B40]; Šmuc et al., [@B76]) might increase local concentrations of estradiol and might decrease the concentrations of progesterone, by its 17-ketosteroid and 20-ketosteroid reductase activities, respectively. Increased levels of AKR1C1, the major human 20-ketosteroid reductase, which is also seen in some endometrial cancer patients, might result in enhanced metabolism of progesterone. Also, in ovarian endometriosis, increased levels of AKR1C3 and AKR1C1 might have similar effects on local estradiol and progesterone concentrations. As the growth of uterine myomas is hormone dependent, AKR1C1 and AKR1C3 might also be associated with the development of these benign tumors.

The AKR1C enzymes are involved in the metabolism of 5α-DHP. In breast cancer 5α-pregnanes have been shown to stimulate cell proliferation and detachment (Wiebe, [@B89]), and also our unpublished studies have confirmed their stimulatory effects on the Z12 endometriotic cell line (Beranič and Lanišnik Rižner, unpublished data). Due to increased levels of 5α-reductase type 1 in endometriosis (Hevir et al., [@B32]), which catalyzes the formation of 5α-DHP, the AKR1C enzymes might be responsible for enhanced formation of its pro-proliferative 3α/β- and 20α-hydroxy-metabolites. Interestingly, *in vitro* the catalytic activity of the AKR1C enzymes can be blocked by progestins (Beranič et al., [@B8], [@B7]), which are used for the treatment of endometriosis, such as medroxyprogesterone acetate and dydrogesterone. Increased levels of AKR1C1--AKR1C3 and 5α-reductase type 1 in endometriosis might thus lead to enhanced metabolism of progesterone toward the formation of 5α-pregnanes (Hevir et al., [@B32]). Also, in some endometrial cancer patients, and especially those who are pre-menopausal, and possibly also in patients with myoma, AKR1C1--AKR1C3 may have a similar role.

The AKR1C enzymes are also implicated in PG biosynthesis, forming PGF2α and 9α,11β-PGF2α (Nishizawa et al., [@B55]; Dozier et al., [@B23]). These PGs have similar affinities for the FP receptor (Dozier et al., [@B23]), and both activate this receptor, which exerts diverse responses via the MAPK signaling cascades, including inflammation and proliferation (Figure [1](#F1){ref-type="fig"}). These actions are mediated through the activation of NF-κB and the inactivation of PPARγ. By converting PGH2 to PGF2α and PGD2 to 9α,11β-PGF2, the AKR1C enzymes prevent the formation of the antiproliferative and anti-inflammatory 15d-PGJ2. This PG covalently modifies, and thus activates, PPARγ, while it inactivates NF-κB (Byrns and Penning, [@B16]). These mechanisms might be used mainly by AKR1C3 but also other AKR1C enzymes in the pathogenesis of cancer endometrium and endometriosis, and possibly also in other uterine diseases.

Similarly as AKR1B enzymes, also AKR1C1 and especially AKR1C3, act as isoprenyl aldehyde reductases (Endo et al., [@B24]) and retinal reductases (Ruiz et al., [@B68]) with higher catalytic efficiencies for GGAL and 9-*cis*-retinal, respectively. As described for AKR1B10 also AKR1C1 and AKR1C3 may be involved in protein prenylation (Figure [3](#F3){ref-type="fig"}) with potential stimulation of proliferation and may also deprive RAR and RXR from their ligand, retinoic acid, which leads to loss of cell differentiation (Figure [2](#F2){ref-type="fig"}). This suggests that inhibitors of AKR1C1 and AKR1C3 would block formation of these prenylated proteins and pro-differentiating retinoic acid. Last but not least, AKR1C enzymes may also be responsible for drug resistance, a frequent and serious problem in treatment of cervical cancer.

Conclusion and perspectives
===========================

In uterine diseases gene expression and the role of the AKR1C enzymes have been most studied among the enzymes of the AKR1B and AKR1C subfamilies. There are several reports on the expression of *AKR1Cs* in endometrial cancer, cervical cancer, and endometriosis, while there are only two studies on the expression of *AKR1B* in endometrial and cervical cancers. Currently, there are no reports showing the presence of the AKR1B enzymes in uterine myomas and endometriosis, nor of AKR1C in uterine myomas.

AKR1B and AKR1C enzymes are involved in processes that are implicated in the pathophysiology of uterine diseases; therefore, it is clear that these enzymes need to be further investigated. First, we need information on the expression of *AKR1B*s and *AKR1C*s in all parts of the human uterus at the mRNA, protein, and cellular levels, and in diseased versus normal tissues. Secondly, the appropriate model cell lines together with overexpression of individual genes and siRNA approach should be used to delineate the enzymatic activities and the involvement of the salient enzymes in the proposed pathways. As specific inhibitors of these AKR1B and AKR1C enzymes have already been developed these can then be tested in these appropriate cell models.

If further studies reveal the involvement of these AKR1B and AKR1C enzymes in the pathophysiology of uterine diseases, these enzymes would represent potential drug targets. The inhibitors would block the biosynthesis of the proliferative PGF2α (AKR1B1, AKR1C3) and estradiol (AKR1C3), formation of prenylated proteins, which may stimulate proliferation (AKR1B10, AKR1C3), the biosynthesis of 9α,11β-PGF2 (AKR1C3), which deprives pro-apoptotic PPARγ of its ligand, and the biosynthesis of retinol (AKR1B10), which decreases the concentrations of retinoic acid and prevents cell differentiation. These inhibitors might block the proliferative effects and the pathological inflammation in the endometrium, myometrium and cervix, and might thus be efficacious as therapies for women with uterine diseases. Furthermore, there is support for these enzymes, and especially for the secretory AKR1B10, to be used as novel diagnostic markers.
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